Ophthorobotics is a brand at the forefront of revolutionizing the treatment of chronic ophthalmic diseases. They are developing the first fully automated system capable of performing safe and precise injections into the eye. With a focus on patient-friendly, robot-assisted intravitreal injections, Ophthorobotics aims to transform the safety, quality, and efficiency of treatment for sight-threatening ocular diseases.

Currently, the leading cause of blindness is age-related macular degeneration (AMD), affecting the central vision of elderly individuals. Ophthorobotics' system offers hope for both wet and dry AMD patients. Wet AMD, characterized by abnormal blood vessel growth in the retina, can now be treated with anti-VEGF injections.

Dry AMD, the most common form, was previously untreatable, but intravitreal injections that slow the advanced stage of the disease have recently received FDA approval. Ophthorobotics addresses major challenges in the standard of care for intravitreal injections. Their robotic injection system enhances safety, decreases procedure times, reduces costs, and allows for integrated data storage and documentation.

With state-of-the-art features like automated ocular alignment, integrated screens for eye movement fixation, and disposable sterilizing patches, Ophthorobotics ensures accurate and sterile injections. Their solution integrates disease management, reduces side effects, ensures safe and reliable injections, and saves time and costs. The system is designed to be operated remotely with AI-enabled diagnostics and electronic patient records, making it a comprehensive and efficient choice for patients and healthcare providers.

Ophthorobotics boasts a team of trusted experts, including CEO and Chairman Bernhard Günther, who brings extensive ophthalmology experience and a track record of successful asset development. With a global network of expertise in ophthalmology, robotics, and AI-driven healthcare, Ophthorobotics is poised to make a significant impact in the field